Uniunea Europeană - română - EMA (European Medicines Agency)

ge healthcare as  - regadenoson - imagistica perfuziei cu miocard - terapia cardiacă - acest medicament este destinat exclusiv diagnosticului. rapiscan este un selectiv coronariană vasodilatatoare pentru utilizare ca un stres farmacologic agent de radionuclizi imagistica perfuziei miocardice (mpi) la pacienții adulți care nu poate să se supună exercitii fizice adecvate de stres.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

millmount healthcare limited - irlanda - regadenosonum - sol. inj. - 80micrograme/ml - alte medicamente pentru afectiuni cardiace alte medicamente pentru afectiuni cardiace

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

krka, d.d., novo mesto - slovenia - theophyllinum - caps. cu elib. prel. - 350mg - alte med. pt. trat. bolilor obstructive ale c.r, sistemice derivati xantinici

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

krka, d.d., novo mesto - slovenia - theophyllinum - caps. cu elib. prel. - 200mg - alte med. pt. trat. bolilor obstructive ale c.r, sistemice derivati xantinici

Uniunea Europeană - română - EMA (European Medicines Agency)

regeneron uk limited - rilonacept - sindroamele periodice asociate criopirinei - imunosupresoare - rilonacept regeneron este indicat pentru tratamentul sindroamelor asociate cryopyrin periodice (capace) cu simptome severe, inclusiv sindrom auto-inflamatorii rece familiale (fcas) şi sindromul muckle-wells (dm), la adulţi şi copii cu vârsta de 12 ani şi mai vechi.

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

regeneron ireland designated activity company - irlanda - cemiplimabum - conc. pt. sol. perf. - 50mg/ml - anticorpi monoclonali

Uniunea Europeană - română - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - carcinom, celule scuamoase - agenți antineoplazici - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.